Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
aUTK8sW4V25RQSNB